Summary of the year-end report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.
The Group
Forth quarter 2025
Income amounted to TSEK 415 (1,090).
Loss before tax totalled TSEK 17,343 (loss: 11,712).
Loss per share was SEK 0.02 (loss: 0.02).
Full year 2025
Income amounted to TSEK 2,282 (4,215).
Loss before tax totalled TSEK 50,158 (loss: 41,534).
Loss per share was SEK 0.07 (loss: 0.07).
The Parent Company
Forth quarter 2025
Income amounted to TSEK 415 (1,090).
Loss before tax totalled TSEK 13,830 (loss: 7,283).
Full year 2025
Income amounted to TSEK 2,282 (4,215).
Loss before tax totalled TSEK 40,856 (loss: 31,508).
Significant events in the forth quarter of 2025
* Xintela announces that Xintela’s oncology subsidiary, Targinta AB, has entered into a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK) Therapeutics Accelerator in New York, USA, for the clinical development of integrin α10β1-targeted antibodies for the treatment of patients with aggressive sarcoma.
* Xintela announces that the last patient has been dosed in the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers.
* Xintela has carried out a rights issue which provided the company with approximately SEK 42 million by way of cash payment and conversion of loans. The company has also taken a loan of SEK 20 million.
* Xintela decides on the issue of warrants to Fenja Capital within the framework of the loan agreement entered into.
Significant events after the end of the period
* Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers.
The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.
